Email ID
Password
Sign me in automatically next time
Nitec's Lodotra positive in second Phase III trial
04 September 2009
Katie McQue

katie.mcque@informa.com

Nitec Pharma's circadian timed-release rheumatoid arthritis product, Lodotra (prednisone), has met its primary endpoint in the second of two Phase III trials designed for a US filing.

The privately-owned Swiss company plans to file the drug in the US in the first half of 2010. It is already...



Please Login to read the full article.
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36